Eyenovia Inc ( EYEN ) shares surged 38.9% to $1.57 on Tuesday morning after the ophthalmic technology firm announced progress in its planned merger with Betaliq and reported an improved first-quarter financial performance.

What To Know: The company extended its exclusive merger negotiation period with Betaliq, a private pharmaceutical firm focused on glaucoma therapies, until June 7, 2025, signaling continued momentum toward a definitive agreement. Eyenovia ( EYEN ) aims to leverage Betaliq's proprietary Eyesol platform alongside its own FDA-approved Optejet delivery technology.

Separately, the company confirmed it remains on track to file for U.S. regulatory approval of its Optejet user-filled device in September, which could unlock new commercial channels. Financially, Eyenovia ( EYEN ) reported a narrower first-quarter net loss of $3.5 million, or $1.59 per share, down from $10.9 million, or $18.75 per share, a year earlier.

Operating expenses fell 70% year-over-year following a broad restructuring initiative and a new debt agreement that defers repayments. CEO Michael Rowe said these efforts are designed to strengthen the balance sheet and position the company for value creation through the potential merger and device approval later this year.

Read Also: Wall Street’s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 4% Dividend Yields

How To Buy EYEN Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Eyenovia’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, EYEN has a 52-week high of $124.80 and a 52-week low of $0.85.